Navigation Links
Increase the Power and Sensitivity for Your cDNA,,,Synthesis with the New Transcriptor Reverse Transcriptase

Transcriptor Reverse Transcriptase is a new recombinant reverse transcriptase (RT) expressed in E. coli. The enzyme has RNA-directed DNA polymerase activity, DNA-dependent DNA polymerase activity, unwinding activity, and, importantly, RNase H activity.

Due to the special recombinant structure of Transcriptor Reverse Transcriptase, the individual enzymatic activities are resulting in a number of unique and beneficial properties.

Achieve High Sensitivity
  • In two-step RT-PCR with the LightCycler Instrument,
Transcriptor Reverse Transcriptase has a broad dynamic detection range of 12 1.2 x 109 copies of in vitro transcribed RNA (Figure 1). This enables analysis of genes with very low or extremely high expression levels.

A linear quantification over 108-fold range of input RNA can be performed with the same efficiency with Transcriptor Reverse Transcriptase, making expression analysis of induced or repressed genes possible (Figure 1).

The high sensitivity of Transcriptor Reverse Transcriptase compared to other reverse transcriptases improves the performance of existing assays and allows performance of assays that were not previously possible (Figure 2).

High fluorescence intensities and well-shaped curves with identical distances for cDNA dilutions lead to clear and interpretable results compared to competitor products (Figure 2).

  • In two-step RT-PCR using conventional thermal cyclers,
As little as 100 pg of total RNA is detected, in combination with the new FastStart High Fidelity PCR System. This enables the analysis of low expressed RNA and RNA when sample material is limited (Figure 3).

  • In one-step RT-PCR using conventional thermal cyclers,
As little as 1 pg of total RNA or 100 fg mRNA is detected, in combination with the Expand High Fidelity PCR System. This permits the analysis of low expressed RNA in one-step RT-PCR.

Obtain Full-Length cDNA Synthesis

cDNA up to 14 kb in length can be generated with Transcriptor Reverse Transcriptase, making it the product of choice for reverse transcription of very long eukaryotic mRNA, as shown in Figure 4 for human dystrophin, one of the longest mRNAs with a length of 14 kb. To achieve high sensitivity and yield in the following PCR, use FastStart Taq DNA Polymerase or the new FastStart High Fidelity Enzyme Blend. Both allow hot-start PCR and are available as single reagents or included in different LightCycler Kits (only Fast Start Taq DNA Polymerase). For amplification of longer fragments, the Expand Long Template PCR System is recommended.

Obtain the Power to Reverse Transcribe the Most Difficult RNAs

Due to the very high thermostability of Transcriptor Reverse Transcriptase (up to 65C) compared to other thermostable reverse transcriptases, robust reverse transcription of GC-rich RNA with high secondary structure can now be easily achieved (Figure 5). In combination with FastStart Taq DNA Polymerase and the GC-RICH Resolution Solution, Transcriptor Reverse Transcriptase is the product of choice when difficult RNAs must be reverse transcribed and amplified in a subsequent PCR.

Rely on a Multi-Purpose Enzyme Tested in a Wide Variety of Assays

Transcriptor Reverse Transcriptase shows premium performance with conventional thermal cyclers and the LightCycler Instrument. Compared to other reverse transcriptases, it is produced under strict regulatory conditions and function-tested in both systems ensuring functionality in end-point and real-time PCR. Additional specifications, such as bioburden, increase the safety level when working with RNA.

Efficiently Label RNA

Efficient incorporation of modified nucleotides during cDNA synthesis is possible, making Transcriptor Reverse Transcriptase an important labeling enzyme in, for example, microarray applications. Labeling with Cyanine 3-, Cyanine 5-, aminoallyl-, DIG-, and Biotin-dUTP was tested; the result was high-efficiency incorporation of these modified nucleotides.

Shorten the Reaction Time

With Transcriptor Reverse Transcriptase there is no need to perform an extra RNase H incubation step following cDNA synthesis as recommended to remove RNA complementary to cDNA when using a RNase H-- mutated reverse transcriptase. RNase H--mutated reverse transcriptase can limit the sensitivity of RT-PCR detection as shown for the gene NCX2, which was detected much more readily when a RNase H step was included after the reverse transcription [1]. If the RNA template is not degraded after first-strand cDNA synthesis, it can bind to the newly synthesized cDNA and restrict its accessibility to primers during subsequent PCR amplification. RNase H-mediated destruction of the template can prevent this problem and improve the sensitivity of RT-PCR analysis.

Additionally, Transcriptor is a fast reverse transcriptase, requiring only 30 minutes for first-strand cDNA synthesis, which results in a reduction of the total reaction time.

Transcriptor Reverse Transcriptase is the product of choice to transcribe RNA (mRNA, total RNA, viral RNA, and in vitro transcribed RNA) from a variety of sources, using conventional thermal cyclers or real-time PCR instruments (e.g., the LightCycler Instrument) for the following applications:
  • Synthesis of first-strand cDNA for use in subsequent amplification reactions
  • RT-PCR of GC-rich RNA templates
  • Incorporation of Cyanine 3-, Cyanine 5-, DIG-, Biotin-, and aminoallyl-modified nucleotides during cDNA synthesis
  • Retrieval and cloning of the 5′ and 3′ termini of mRNA by RACE (Rapid Amplification of cDNA Ends)
  • Generation of cDNA libraries with large inserts.

Transcriptor Reverse Transcriptase is supplied in storage buffer with a volume activity of 20 U/l. A 5x concentrated reaction buffer is also provided.


'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Increased Sensitivity in Microarray Analysis
2. Increase Protein Activity and Yield
3. Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell
4. Increase Your Organizations Productivity with LabVIEW
5. Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery
6. 140-Fold Increase of Protein Achieved in Pichia Fermentation
7. A Versatile Power Supply for All Electrophoresis Applications
8. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
9. 2100 expert software Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer
10. Temporal Temperature Gradient Electrophoresis: A Powerful Technique to Screen Mutations
11. National Instruments DIAdem -- Complete Your Technical Data Management Framework with Powerful Off-line Analysis, Visualization, and Report Generation
Post Your Comments:
(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... Francisco, CA (PRWEB) April 30, 2015 Cytokinetics, ... the first quarter of 2015 were $4.4 million, compared to ... net loss for the first quarter was $8.9 million, or ... a net loss for the same period in 2014, of ... As of March 31, 2015, cash, cash equivalents and investments ...
(Date:4/30/2015)... 30, 2015 Biodata, producer of ... integrated protocols and specimen management systems, and ChemAxon, ... consulting services for life science research, announce their ... newest feature: chemical structure and reaction support. Already ... biologists, bio-chemists, and more, the integration of ChemAxon's ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Agence de Medecine,Preventive (AMP) announced today the appointment ... SIVAC (Supporting Independent Immunization and,Vaccine Advisory Committees) initiative. ... national immunization technical advisory groups in six,resource poor ... committees will help,national health authorities to set up ...
... 12 Synvista Therapeutics, Inc. (NYSE Alternext ... BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of ... the effect of alagebrium on exercise tolerance in patients with ... enrollment of its BREAK ( B eginning a R ...
... ANA, Calif., Jan. 12 ,Abbott ( NYSE: ABT ) and ... a definitive agreement for Abbott to acquire AMO for $22 ... $2.8 billion, inclusive,of estimated net debt at the time of ... leader in ophthalmic care, comprised of three segments: cataract,surgery, laser ...
Cached Biology Technology:French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 2French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... University previously developed ion transistors for transport of both ... has now succeeded in combining both transistor types into ... electronics. An advantage of chemical circuits is ... various functions. This means that we now have new ...
... diseases, the St. Jude Children,s Research Hospital Washington ... release of comprehensive human cancer genome data for free ... information released more than doubles the volume of high-coverage, ... sources combined. This information is valuable not just to ...
... collaboration between scientists from the Experimental Therapeutics Centre (ETC) under ... from Tan Tock Seng Hospital (TTSH) has enabled the successful ... test kit available to date. With this highly advanced kit, ... H5N1 viruses in a single test with almost 100% accuracy, ...
Cached Biology News:World's largest release of comprehensive human cancer genome data helps speed discoveries 2World's largest release of comprehensive human cancer genome data helps speed discoveries 3Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 2Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 3